All News

Celebrating my 10,000 followers on TikTok. @Rheum101 is where I make videos teaching rheumatology to the general public in 3 min bites. Topics include #SLE #Steroids #RA #ANA #RheumLabs #DMARDS #biologics #JAKi #osteoporosis #PsA and more #RheumEducation #NotMedicalAdvice https://t.co/WEXspp5v28
TheDaoIndex KDAO2011 ( View Tweet)
RheumNow Podcast square

Infections & Lupus (10.28.2022)

d Jack Cush, MD

Dr. Jack Cush discusses the news and journal reports from the past week on RheumNow. This week more lupus nephritis, more drug induced lupus and more lupus infections that may kill. 

Read Article
RA is an independent risk factor for Thyroid Dz & AITD. Study of 250 RA & 248 non-inflammatory RMD controls. RA had more abnl TFTs (34% v 19%; OR 2.2), Overt hypothyroidism, Anti-TPO Abs, & AITD (21.5% vs 9%; OR 2.8). https://t.co/lRvY4VGkUc https://t.co/ibUqPiD9Bv

Links:

Dr. John Cush RheumNow ( View Tweet)
biosimilars2.jpg

Growing Confidence in Biosimilars?

d MediaSource

Today, Cardinal Health released its third edition of Rheumatology Insights, a research report based on surveys with more than 100 rheumatologists nationwide that focuses on key trends

Read Article
Will we see you there? #ACR2022 What are you most looking forward to on the agenda? https://t.co/KQGHJtwboe
Dr. John Cush RheumNow ( View Tweet)
Increasing Prevalence of RA, PsA and AS in the UK Electronic health record (EHR) database analysis from the United Kingdom suggests an increasing number of rheumatoid arthritis (RA), PsA and SpA patients in England. https://t.co/Rtt5dvFc17 https://t.co/rPsvq3nlXl

Links:

Dr. John Cush RheumNow ( View Tweet)
happy,patient,remission,wait

New ACR/EULAR Guideline Expands RA Remission Definition

d MedPage Today

Newly released guidance for defining remission in rheumatoid arthritis (RA) is expected to increase the number of patients achieving it while maintaining its ability to predict good objective outcomes.

Read Article
TNF inhibitors Dont Increase Cancer Risk! 4592 RA pts:TNFi Rx (2296) vs matched DMARD Rx (2296) pts. TNFi had a lower cancer risk than DMARD Rx (IR 6.5 vs. 15.6 /1000PYs]). TNFi had Lower HR GI CA (0.432), breast CA (0.146), GU CA (0.220) https://t.co/F5ToHLJULn
Dr. John Cush RheumNow ( View Tweet)
Mayo Clinic Biobank matched case-control study (1:3) of 212 incident RA cases Active work physical activity lowered risk of RA (aOR 3.00), while 3-5 servings high-fat foods, fruits/vegetables lowered risk (OR 0.45; OR 0.54). https://t.co/AAQ1nRfJXq https://t.co/72yLQUllDV

Links:

Dr. John Cush RheumNow ( View Tweet)
1915 Rheumatic (RMD)pts w/ COVID (42% RA. 15% SLE, 1/2 comorbidities); Outcomes: 28% hospitalized, 8% to ICU & 4% died from COVID-19. Poor COVID-19 outcomes seen w/ age, male, Hi Dz activity, steroids & RTX, & 1+ comorbidity https://t.co/ztBiJc9nxV https://t.co/RVOKyjseFJ

Links:

Dr. John Cush RheumNow ( View Tweet)
risk.time_.jpg

Increasing Prevalence of RA, PsA and AS in the UK

d Jack Cush, MD

Electronic health record (EHR) database analysis from the United Kingdom suggests an increasing number of rheumatoid arthritis (RA), psoriatic arthritis (PsA) and axial spondyloarthritits (SpA) patients in England.

Read Article
Tawanese claims analysis of 10,857 RA pts shows lower CVA rates when taking Celebrex (5.95% vs 9.72% not taking) or Etoricoxib (2.69% vs 8.51% not taking). Both Celebrex/Etoricoxib significantly reduced stroke risk p < 0.001 https://t.co/6idrH9g0LJ https://t.co/d80bEtsP7k

Links:

Dr. John Cush RheumNow ( View Tweet)
Follow us for real time coverage #ACR2022 https://t.co/5CBdiKWdKM
Dr. John Cush RheumNow ( View Tweet)
Prevotella Immune Response in Both Pre-Clinical & Established RA In a recent analysis published in Arthritis & Rheumatology, people at risk for RA and those with the disease had elevated blood levels of antibodies against a Prevotella copri (Pc). https://t.co/6zArTx4XlM https://t.co/9UIk2OOhXq

Links:

Dr. John Cush RheumNow ( View Tweet)
Difficult to treat RA (D2T-RA) study of 48 D2T-145 non-D2T-RA pts. D2T-RA was predicted by Not starting MTX w/in 3 mos (17% vs 33% non-D2T-RA;p= 0.011) &being on steroids > 6 mos (71% vs 34%, p< 0.001). https://t.co/Ugbr7z7mia https://t.co/TCU7wSfMrS

Links:

Dr. John Cush RheumNow ( View Tweet)
microbes.jpg

Prevotella Immune Response in Both Pre-Clinical & Established RA

d EurekAlert! and Jack Cush

In a recent analysis published in Arthritis & Rheumatology, people at risk for rheumatoid arthritis (RA) and those with the disease had elevated blood levels of antibodies against a Prevotella copri (Pc). 

Read Article
Miner,coal,newcastle

Miners Face Increased Risk of Rheumatoid Arthritis

d MedPage Today

Add "hard rock" mining to the list of occupations associated with high rates of rheumatoid arthritis (RA), a new study indicated, with silica exposure the presumed malefactor.

Read Article
Rheumatology Salaries and Career Choices A recent Doximity report shows how rheumatology salaries increase by years in practice. Rheumatologists tend to earn their highest salaries after gaining 30-39 years of experience. https://t.co/wxWQruIlu9 https://t.co/gUsIffoHn6

Links:

Dr. John Cush RheumNow ( View Tweet)
Review of risk factors for osteoporosis and fractures in #RA. OP Risk factors same as gen population (but more prevalent in RA) - smoking, calcium intake, vit D deficiency, hypogonadism and chronic exposure to glucocorticoids https://t.co/KsE5ag29ZN https://t.co/OQtfoKcIX2

Links:

Dr. John Cush RheumNow ( View Tweet)
undifferentiated,arthritis,early,RA

Second Efforts in Treating RA Partial Responders

d Jack Cush, MD

The results of a treat-to-target (T2T) combination therapy trial in patients with early rheumatoid arthritis (RA) show that if patients fail to respond initially, then a second, more intensified regimen can turn initial nonresponders into responders.

Read Article

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright {{ 'now'|date('Y') }} All Rights Reserved.